Navigation Links
Accera, Inc. Completes $35 Million Series C Financing
Date:11/11/2008

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona(TM) (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009.

Inventages was joined in this round by San Diego-based POSCO BioVentures and other previous private investors. Inventages and POSCO participated in the Company's Series A and B rounds.

Steve Orndorff, Ph.D., Accera's founder and CEO, said, "Closing this transaction in the current difficult financial environment is a testament to the confidence of our investors in the Accera organization and the potential of Axona".

Wolfgang Reichenberger, Ph.D., general partner, Inventages WHealth Management Inc. and IVC Americas SA and a member of Accera's Board of Directors, expressed enthusiasm about the commercial direction of the company and the upcoming launch of Axona. "Metabolic intervention is a new approach to neurodegenerative diseases, and Accera is a clear leader. We are pleased to support the commercialization of Axona as the lead product from this novel technology platform," Reichenberger said.

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies by providing an alternative energy source for the brain. For more information, visit http://www.accerapharma.com.

Contacts

Media: Investors:

Kelly McKenna Greg Kading

MS&L Worldwide Vice President, Finance

(415) 293-2808 Accera, Inc.

Kelly.mckenna@mslworldwide.com (303) 999-3704

gkading@accerapharma.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
2. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Avantium Completes EUR 18 Million Financing Round
5. Advanced Life Sciences Completes Debt Transaction
6. American Oriental Bioengineering Completes Two Acquisitions
7. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
8. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
9. S*BIO Completes US$26 Million Equity Financing
10. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
11. CeNeRx BioPharma Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):